Travere Therapeutics Inc logo

TVTX

Travere Therapeutics Inc

$26.93

Earnings Summary

Revenue
$54.17Mn
Net Profits
$-67.03Mn
Net Profit Margins
-123.75%

Highlights

Revenue:

Travere Therapeutics Inc’s revenue fell -0.82% since last year same period to $54.17Mn in the Q2 2022. On a quarterly growth basis, Travere Therapeutics Inc has generated 11.71% jump in its revenue since last 3-months.

Net Profits:

Travere Therapeutics Inc’s net profit fell -71.82% since last year same period to $-67.03Mn in the Q2 2022. On a quarterly growth basis, Travere Therapeutics Inc has generated 11.77% jump in its net profits since last 3-months.

Net Profit Margins:

Travere Therapeutics Inc’s net profit margin fell -73.25% since last year same period to -123.75% in the Q2 2022. On a quarterly growth basis, Travere Therapeutics Inc has generated 21.02% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Travere Therapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.88
EPS Estimate Current Year
-0.88

Highlights

EPS Estimate Current Quarter:

Travere Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.88 - a -3.53% fall from last quarter’s estimates.

EPS Estimate Current Year:

Travere Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.88.

Key Ratios

Key ratios of the Travere Therapeutics Inc post its Q2 2022 earnings

Return on Assets (ROA)
-0.13
Return on Equity (ROE)
-0.7
Dividend Per Share (DPS)
0

Highlights

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Travere Therapeutics Inc’s return on assets (ROA) stands at -0.13.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Travere Therapeutics Inc’s return on equity (ROE) stands at -0.7.

Dividend Per Share (DPS):

Travere Therapeutics Inc declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-05
-0.85
-1.2
-41.18%

Company Information

Travere Therapeutics is a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, the company knows the need for treatment options is urgent - that is why its global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, Travere continuously seeks to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope - today and tomorrow.

Organisation
Travere Therapeutics Inc
Employees
262
Industry
Health Technology